A REVIEW ON TUBERCULOSIS AND ITS TREATMENT

ABSTRACT

Mycobacterium tuberculosis, which causes tuberculosis (TB), is a deadly infection that often affects the pulmonary system of humans and causes severe coughing, fever, and chest pain. Tuberculosis is spread through the air and is lethal. Although ongoing studies on tuberculosis during the past few years have yielded useful knowledge regarding the disease's spread, detection, and treatment. Because it has the second-highest fatality rates after HIV/AIDS, tuberculosis strains public health. In order to scale up the TB response, the WHO (World Health Organisation) is closely collaborating with nations, partners, and civil societies. This review article will concentrate on the epidemiology, diagnosis, signs, and treatment of tuberculosis (TB) and provide information on the most recent findings about the pathophysiology, immune response, appropriate care, and control of TB. Assays for interferon-gamma release are Entire blood tests are effective in TB diagnosis but fall short in separating tuberculosis infection from tuberculosis illness.Despite the fact that an effective treatment has been available for more than 50 years, since the 1940s, tuberculosis (TB), an old disease caused by the bacteria Mycobacterium tuberculosis, still causes more deaths globally each year than any other infectious disease, including the human immunodeficiency virus (HIV). One of the major difficulties facing the effort to stop this deadly epidemic is the emergence of antibiotic resistance. The disease's widespread geographic distribution exacerbates practical concerns such a lack of community knowledge, access to diagnostic equipment, healthcare facilities, and patient supervision and follow-up. . It is similarly problematic when local and international control units are unable to communicate and coordinate. There is a need for a greater effort to mobilise resources and make long-term, targeted investments of funding and professional training in regions with endemic TB if we are to finally put an end to this bacteria's enduring reign of devastation. This is true even as we continue to make great strides in medical technology and research. This review article examines the disease's current global developments from a more comprehensive angle.

Keywords*: Tuberculosis pathogenesis Immunology Tuberculosis diagnosis Tuberculosis treatment.*

INTRODUCTION

In India, there are more than a million cases of tuberculosis every year. Mycobacterium tuberculosis is the culprit. Typically, it affects the pulmonary region of the body, but if left untreated, it can also affect other areas. The World Health Organisation (WHO) stated in 1990 that TB was the eighth most lethal disease in the world1 in its report on the Global Burden of Disease. According to a 2001 WHO estimate, 32% of the world's population has TB. Almost 8 million people worldwide get TB each year, and 2 million patients pass away from inappropriate care. A potentially dangerous infectious condition that mostly affects our lungs is tuberculosis. Tuberculosis-causing bacteria are transferred from one person to another by little droplets in the air that are emitted during coughs and sneezes2.Compared to HIV or any other infection, tuberculosis (TB) consistently shows a substantially higher yearly fatality rate. This is caused by a series of circumstances, beginning with the virulence of Mycobacterium tuberculosis, the bacterium that causes TB illness and is extremely contagious and persistent. The capacity of these bacteria to undergo genetic alterations that impart resistance to a variety of previously effective antibiotics is another significant reason. In 2013, the World Health Organisation (WHO) predicted that 480,000 cases of TB that were resistant to several drugs had been found globally. Since effective antibiotic therapies for TB were identified, MDR-TB and its more resistant brother, extensively-drug-resistant (XDR-) TB, have become more prevalent. Unsettlingly, some specialists believe that in the next 50 years, MDR-TB will overtake non-resistant TB as the most prevalent type of the illness.

[1]. However, there has been significant progress in the creation of efficient methods for infection control, treatment, and preventative care. Global health organisations are prepared to build on the downward trend in the yearly mortality rate of tuberculosis (TB) since 1990. It has even been said that 2015 marks a turning point in the fight against tuberculosis following ten years of public health initiatives and research.

[2]. Healthcare practitioners will be able to achieve significant advancements in this high-stakes struggle by combining tried-and-true care and management strategies with promising new tools for better TB detection and treatment. Despite this progress, TB control receives significantly less financing than other infectious diseases. It is abundantly clear that current finance and communication shortages are hampering prevention and control efforts, but strategic investments will have a tremendous impact on the global drive to stop this crippling illness.

HISTORY

Since the last 150 million years, mycobacterium has existed on earth. Mummies from the pre-Columbian periods in Peru and Egypt both have typical tubercular spinal lesions.The earliest tenuous proof of tuberculosis in humans comes from a bone lesion discovered in a 500 000 year old skull in Turkey. Patients with Mycobacterium tuberculosis, an airborne disease that typically affects the pulmonary region and causes severe coughing, fever, and chest pains, were advised to "just sleep and eat nutritious foods" in the 1800s.3 . Robert Koch, a German microbiologist, wrote in 18824 that Mycobacterium tuberculosis causes TB in humans. Since ancient times, TB or illnesses similar to TB have been reported in several civilizations. In the Vedas, the first such description is recorded. TB was known as Yakshma, which is Sanskrit for "wasting disease". Literature from Greece, China, and the Arab world also mentions TB-like illness. This ground-breaking discovery was followed by the development of tuberculin in 1890–1855. As AIDS spreads, TB rates rise once more, which sparks doctors' interest in the disease's research and prevention3. The diagnostic and therapeutic methods required to battle TB have significantly changed in recent years, and Directly Observed Treatment Short-Course (DOTS) therapy and a DOTS-plus programme to address multidrug-resistant (MDR) TB first appeared as plans to control the disease in the early 1990s. Even while current TB research has produced useful information regarding TB transmission, detection, and comprehensive treatment, much more needs to be developed in order to significantly reduce the incidence of TB3-6. The Bacillus Calmette Guerin (BCG) vaccine was developed to prevent tuberculosis throughout the 20th century, but despite widespread use, it hasn't been able to stop the disease's spread in densely populated places. The BCG vaccine's inconsistent efficacy in halting the spread of adult pulmonary TB is a contributing factor in the ongoing rise in infections in such underdeveloped areas even after vaccination. Mycobacterium tuberculosis transmission via active pulmonary illness occurs after TB transmission has continued. There is an immediate need for a more effective TB vaccination.7. 4,90,000 cases of multidrug resistant (MDR) TB were found, and only 50% of patients who got the recommended WHO treatment regimens6-7 survived. The report details the need for innovative treatments and access to further develop the delivery of TB treatment and management conclusions. Creating the best treatment plans for tuberculosis still faces several obstacles. Combined Shorter durations, more effective, safe, and better tolerated treatment regimens are being developed in an effort by stakeholders, advocates, and researchers. For MDR TB, only three innovative medications have reached an advanced stage of development, while nine more are being examined in phase 1 and phase 2 studies. Instead of developing new medications, a number of immune-based therapies and host-directed therapies are being developed to eradicate Mycobacterium tuberculosis infection. These therapies aim to shorten the length of treatment, prevent lasting lung damage, and prevent the emergence of new drug resistance.8-10 . One of the oldest organisations tackling TB-related health issues is the International Union against TB. The first was 'Tuberculosis' was first published in French, German, and English in 1902 when the company was officially registered. Its main objective is to treat countless TB patients in underdeveloped nations via the National Tuberculosis Programme (NTP). This programme is designed to give the Basic Management Unit (BMU) of NTP's task-holder, who is frequently a paramedical professional like as a nurse or pharmacist, the necessary skills. This is being done with the intention of disseminating this knowledge to the general population who are TB11 patients.

EPIDEMIOLOGY

According to reports, MTB9 is present in 1/3 of the world's population. Latent infections have the potential to become active infections 7-8. A very significant risk exists in 5 to 10% of LTBI cases as a result of their transition from a passive infection to active (primary) TB. A extremely high risk of developing active TB12 exists in people with HIV and other immunocompromised conditions, such as cancer patients or those who are currently taking immunosuppressive treatment. According to Robert Koch, TB is significantly more lethal than cholera or plaque. Approximately 9 million people worldwide have TB, and 1.5 million individuals worldwide have TB infection. only TB was the cause of more than 2.5% of all fatalities worldwide in 2004.9 Infection rates are quite high in places like hospitals or prisons6. The war against TB stopped in 20135. TB spread in these locations is influenced by virulence, innate immunity, and sensitivity7-8. While occurring in underdeveloped nations with limited resources, namely in India and China4,6. 80% of HIV+ people who have TB live in sub-Saharan Africa and are very susceptible to contracting the disease.6-10. United States, Only 10% of TB patients in a country with smaller population are HIV positive. 12,904 TB cases, or 4.2 per 100,0003, were reported in

2008. Despite improvements in diagnostic technology over the previous four years, more than twenty-two nations, including India, Pakistan, Nigeria, Bangladesh, China, Indonesia, South Africa, and Russia6, account for 80% of all TB cases worldwide.TB can strike anywhere in the world, although the bulk of fatalities—roughly 95%—have been observed in

PATHOGENESI

Only a small portion of droplet nuclei containing MTB from infectious individuals reach alveoli; the bulk are retained in upper airways and ejected by ciliated mucosal cells. The mycobacteria subsequently attach to the alveolar macrophages' cell surfaces via the complement, mannose, or type A scavenger receptors. Mycobacteria diminish the phagosome's acidity after phagocytosis, and a component of the cell wall called lipoarabinomannan damages the Ca/calmodulin pathway, which prevents the fusion of the phagosome and the lysosome.After the phagosome maturation process is successfully stopped, the bacilli multiply and the macrophage eventually bursts to release the bacilli. Macrophages then restart the infection cycle, furthering the spread. 22MTBbacilli undergo hematogenous and lymphatic spread during primary infection, engaging the hilar and mediastinal lymph nodes to produce the primary Ghon's complex. Bacilli eventually enter the bloodstream and travel to other organs.

ETIOLOGY AGENT

Mycobacterium tuberculosis

Infection with M. tuberculosis has been recognised throughout human history. It is thought that the bacterium came from East Africa. Early people left East Africa and settled in Europe and Asia, and the TB illness followed them and wreaked havoc for ages across the known world [3]. Mummies from the pre-dynastic period in Egypt and the pre-Columbian period in Peru, which began approximately 2400 B.C., both showed signs of tubercular degeneration on their spines [4]. Phthisis was the term for the sickness in ancient Greece. The "Great White Plague" of tuberculosis afterwards ravaged Europe for more than a century. During this time, the illness was thought to be nearly always deadly, and there was no proven therapy or cure [3].

When Hermann Heinrich Robert Koch presented "Die Aetiologie der Tuberculose" to the Berlin Physiological Society, he made a significant discovery on the aetiology of tuberculosis. On March 24, 1882, he presented his findings, and in 1905, he was awarded the Nobel Prize. This marked the beginning of an era in which the prevention and treatment of this fatal illness made unheard-of advancements [5]. Another significant event occurred in 1943 when the antibiotic streptomycin, the first treatment for the infection, was found in a lab at Rutgers University in New Jersey. The first documented drug trial to randomly assign participants was the first large-scale clinical trial of streptomycin, which was conducted at the British Medical Research Council in 1948. This study established contemporary randomised controlled trials' methodological gold standard. Patients also displayed streptomycin resistance for the first time. Thiacetazone and paraaminosalicylic acid, two further anti-tuberculosis medications, also hit the market in 1948. Streptomycin administration combined with either of these medications significantly improved cure rates and reduced bacterial acquired resistance [6,7].

In 1951, isoniazid underwent satisfactory testing and was added to the TB treatment plan. This was followed by the creation of other new medications, including pyrazinamide.

Methods

For this study, recognised risk factors were sought after using the databases PubMed, Medline, and EMBASE. The search was restricted to investigations of risk variables influencing TB infection and illness and only included papers written in English. TB treatment outcomes-related factors like mortality and default were excluded. In addition to "tuberculosis," "risk factors," and "transmission" as text words AND infectious diseases, "tuberculosis," and "risk factors" as MeSH or topic terms and keywords, broad search terms included the following: "tuberculosis," "transmission," and contacts as a MeSH or heading term. In other Tuberculosis periodicals, including the International Journal of Tuberculosis and Lung Disease, more specific searches were conducted. Indian Journal of Tuberculosis, the Bulletin of the World Health Organization, and the Indian Journal of Medical Research. Only major risk factors related to TB infection and disease were identified, relevant literature was reviewed, and factors influencing TB treatment outcomes were not included.

TREAMENT / MANAGEMENT

Latent Tuberculosis

The NTCA and CDC recommended treatment regimens for 2020 LTBI include two alternate monotherapy regimens with daily isoniazid and three preferred rifamycin-based regimens. These are only advised for those with Mycobacterium tuberculosis infections who are thought to be isoniazid or rifampin susceptible. For adults and children older than 2 years old, the ideal regimen is 3 months of once-weekly isoniazid in addition to

rifapentine. Rifampin for 4 months daily is an additional alternative for HIV-negative adults and kids of all ages. The preferred therapy is daily isoniazid plus rifampin for three months. All ages of adults, children, and HIV patients are conditionally advised. Alternative suggested regimens include isoniazid regimens of 6 or 9 months.

Treatment of Active Infection

Combination medications are necessary for the treatment of confirmed TB. It is always recommended to employ combination medication rather than monotherapy while treating tuberculosis. The following anti-TB drugs are part of the most typical TB treatment regimen:

First-Line Medications, Group 1

- Isoniazid -

Adults: 15 mg/kg (900 mg) once, twice, or three times per week; 5 mg/kg (300 mg) daily (maximum).Children: 15-20 mg/kg (300 mg) twice a week; maximum: 10-15 mg/kg (300 mg) each day (3).Preparations. tablets (50 mg, 100 mg, 300 mg); syrup (50 mg/5 ml); and an aqueous solution (100 mg/ml) for intravenous or intramuscular injection.

- Rifampicin

Adults: 10 mg/kg (600 mg) once per day, twice per week, or three times per week (maximum).Children: 10–20 mg/kg (600 mg) twice weekly or once daily (maximum).Preparations. (150 mg, 300 mg) capsules

- Rifabutin-

Adults: 5 mg/kg (300 mg) daily, twice daily, or three times per week (maximum). Rifabutin dosage should be increased to 450–600 mg daily or on occasion when used with efavirenz.Maximum number of kids: There is no known safe dosage for children. Capsules (150 mg) for oral use are the preparations.

- RIfapentine –

Adults (maximum): 10 mg/kg (600 mg), once per week (treatment continuation phase)Children: The medicine has not been given the go-ahead for use in kids.Preparation. 150 mg film-coated tablet.

- Pyrazinamide

20–25 mg/kg per day for adults.

Children: (maximum) 15–30 mg/kg (2.0 g) per day; (maximum) 50 mg/kg (2.0 g) twice weekly.Preparations. (500 mg) Tablets.

- Ethambutol -

Adults: daily dose of 15-20 mg/kg: Children: 50 mg/kg twice weekly (2.5 g), or a maximum of 15-20 mg/kg each day (2.5 g). When administered to older children, the medication can be used without risk, while younger children, often those under the age of five, should be administered with caution (66). If there is a worry about INH or RIF resistance in young children, EMB may be utilised.Preparations. tablets (100 mg, 400 mg) intended for oral use.

Isoniazid and Rifampicin are used as a 4-drug regimen for 2 months or 6 months, typically consisting of Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide. Isoniazid is always administered in combination with vitamin B6 to avoid neuropathies.

The following classes of additional antimicrobials are efficient against tuberculosis:

Summary of Specific Risk Factors

The main traits that affect a person's likelihood of developing an infection or disease are shown in Figure 1, and the important risk factors are listed below. Factors Associated with the Index Case Bacillary Load, or 3.1.1. Smear-positive cases are more contagious than the other cases, according to epidemiological research done in the middle of the 20th century [11, 12]. Each smear positive case can result in two new cases of TB, at least one of which will be contagious, and an untreated sputum positive patient can infect about 10 others annually [2, 13].

[The amount of bacteria in a TB patient's sputum is positively connected with how contagious the patient is. In their prospective study of 803 household contacts of 174 index TB patients in the Dominican Republic, Espinal and colleagues examined the impact of HIV on the infectiousness of Mycobacterium tuberculosis by giving the contacts 5 TU Tubersol PPD at baseline and then following them up at 2, 8, and 14 months. They demonstrated in their subanalysis that contacts with an index case sputum smear grade of 1–10 (bacilli per field) and >10 (bacilli per field) had increased probabilities of TST positivity when compared to 0(bacilli per field) were 1.98 (CI = 0.75-5.23) and 5.88 (CI = 1.60-21.3), respectively. This demonstrates unequivocally that exposure to higher-grade sputum from an index patient increased the risk of a positive TST [14]. The quantity of M. tuberculosis bacilli that can cause infection can be as little as one to ten bacilli, according to experimental studies, which demonstrate that smear negative patients are predicted to have fewer bacilli than smear positive patients but can still spread the infection [15]. According to epidemiological studies (prevalence and incidence studies) carried out in the USA, UK, and India, the prevalence of infection and disease is higher among contacts of smear positive index cases than smear negative cases.

cases, while smear-negative individuals had greater rates than the general population [18–27]. 71 clusters of patients with the same strains of infection were found by Behr et al. in their molecular investigation in San Francisco, and out of 183 secondary cases in those clusters, 17% [28] were attributable to infection by smear negative individuals [29], with the remaining cases being smear positive. Similar investigations carried out in the Greater Vancouver regional district by Hernandez-Gardu' el and colleagues revealed that the episodes of transmission from smear negative clustering patients ranged from 17.3 to 43.2. 25 to 41% among the extra pulmonary group and 18.8% to 22.2% in the pulmonary group [15, 30]. 13% of the secondary cases, according to Tostmann from the Netherlands [31], were caused by transmission from smear-negative patients. According to this, individuals with sputum-positive diagnoses are more likely to be contagious [10, 12, 28, 32], while smear-negative cases continue to be a significant source of transmission. Proximity to an Infectious Case (3.1.2). Close contacts of infectious TB cases, such as household members and caregivers/health care professionals, are more likely to contract Mycobacterium tuberculosis and develop primary active disease [33].

tuberculosis. Large epidemiological surveys [20, 36–38] and household contact studies among TB patients from the early 20th century [11, 34, 35] have proven this effect. To ascertain the effectiveness of home contact research, Morrison and colleagues conducted a systematic review [39]. 41 studies, carried out in 17 nations (49% in Africa, 29% in Asia, and 22% in Central and South America), were included by the authors.When all contacts were looked at, the yield for cases with bacteriological confirmation was 2.3% (CI = 2.1-2.5) and for instances with clinical diagnosis, it was 4.5% (CI = 4.3-4.8). Infection with latent tuberculosis was discovered in 51.4% (CI = 50.6-52.2) of the contacts analysed. However, there were restrictions, such as the presumption that illness genesis and transmission happened without To determine whether the results are above the community average, researchers used biological evidence of organisms and the absence of population tuberculosis rates. The majority of studies used TST to identify LTBI, however the test's interpretation is constrained by false positive and false negative results [40]. A subgroup study of index cases with positive sputum smears revealed a pooled yield for long-term disability of 51.8% (CI = 50.9-52.8).

A person with no risk factors has a much lower probability of developing TB disease than a person with LTBI (confirmed as TST positive). This conclusion has been made by numerous investigations. Ferebee [41] conducted two controlled clinical trials to evaluate the effectiveness of LTBI treatment in patients. The tuberculin skin tests of 1472 participants in the placebo groups of the trials changed from negative to positive among contacts of people with active TB and among patients in mental facilities. In the group of individuals whose tests converted, 19 cases of disease arose in the first year of follow-up (12.9 cases per 1000 person-years), compared with 17 cases in the following 7 years of follow-up (1.6 cases per 1,000

person-years) [41]. An research into an epidemic on an aeroplane provided a convincing illustration of the impact of proximity to an infectious case. In comparison to the rest of the section, passengers who were seated within two rows of the index TB patient were more likely to have a positive tuberculin skin test (30.8% versus 3.6%, RR = 8.5, CI = 1.7-41.3) [42]. According to the "stone in the pond" theory, which holds that the risk of infection rises with proximity, contact tracing efforts have consequently been focused on family members of TB cases [43]. However, the significance of TB transmission in the community has long been contested. Blomquist [44] brought up the problem of defining contacts of a case and emphasised the need to broaden the definition of "contact" to include more people connected to each patient, suggesting that transmission occurs outside of households. The product of the risk and the number of infection cases in a specific exposure group (defined by proximity to the source case) as well as the size of the group. There appear to be more cases of infection in the very large group of distant, low risk contacts than in the small group of close, high risk contacts, supporting the Rose axiom [45] that "a large number of people at small risk may give rise to more cases than a small number of people at high risk." A fraction of the infected contacts (20%) are identified by conventional contact tracing, which often reveals close, high risk contacts. This requires widening the tracing circle [46]. Early epidemiological investigations that revealed that the majority of older children with a positive TST had no household contact with a source case and were thus likely to have been infected in the community [19, 47–49] highlighted the significance of casual encounters. In their retrospective analysis of a significant dataset, Narain and colleagues An Indian household survey [20] revealed that just 2% of the community's total infected individuals belonged to case families, 7% to suspect case households, and the remaining 91% of cases belonged to noncase households. The zone of influence of an infected case may reach residences at least 10 lots away, according to the scientists [50]. Radhakrishna et al. reported similar findings in their 15-year follow-up study of 253261 people in rural south India [26].

The significance of incidental transmission in both high- and low-incidence situations has also been supported by molecular analyses that pinpoint the strain of the TB organisms. In the USA, Bishai and colleagues were able to demonstrate that widespread TB transmission takes place in the neighbourhood. A total of 84 (46%) of the 182 individuals with isolates available displayed molecular clustering, with 58 (32%) being classified as having been recently transmitted. Of the 84 instances with clustered DNA fingerprints, only 20 (24%) provided epidemiological proof of recent interaction. Young age, homelessness, alcohol and drug use, as well as demographic characteristics like geographic aggregation in an area, were socioenvironmental risk factors for incidental exposure to infectious TB patients that were shared by the 64 remaining (76%) cases without epidemiological linkages. a neighbourhood with subpar housing [51]. These results suggest that TB is still spread through unintentional recent transfer. Other studies from low-incidence environments also came to similar conclusions [52–56]. In a similar vein, Narayanan and colleagues' extensive field investigation in south India revealed that 62% of patients (236/378) shared the same strains, indicating a highly high casual transmission [57]. This has been supported by studies conducted in other endemic regions, such as South Africa [58, 59].

These investigations demonstrate that TB can spread rapidly by touch [60], even in unconventional settings where there are many opportunities for such contacts. environment with elevated infection pressure, poverty, and overcrowding [61]. Therefore, casual transmission is a crucial component of TB dynamics in endemic conditions [62].

Clinical features

Since EPTB is less frequent than PTB, doctors meet it less frequently and find it more challenging to detect clinically.

1. Miliary TB

Clinical signs, which can include fever, weight loss, night sweats, anorexia, and weakness, are typically non-specific. Fever, wasting, hepatomegaly, pulmonary findings, lymphadenopathy, and splenomegaly are the physical signs, listed in decreasing order. Granulomas in the retinal choroid are a highly suggestive sign of widespread tuberculosis.

2.TB Lymphadenitis

It first manifests as a painless swelling in the supraclavicular fossa of the neck. The procedure is often bilateral, and as the disease advances, the lymph nodes fuse and mat together. The skin that lies on top becomes swollen, and eventually, larger lymph nodes rupture through the swollen skin, generating a sinus tract. By squeezing the bronchi or causing bronchiectasis (common in children), intra thoracic adenopathy may result in atelectasis.

3.Pleural TB

The quantity of germs that have infected the pleural space determines how tubercular pleurisy presents. Few MTB bacilli entering the pleural space trigger a hypersensitive reaction that causes a pleural effusion. The process may end on its own or it may result in a massive effusion that brings on symptoms including fever, pleuritic discomfort, dyspnea, and weight loss. Tubercular empyema results from a large number of MTB bacilli entering due to a cavity rupture or an adjacent parenchymal fistula. HIV seropositive patients with pleural TB present with chronic disease and extra symptoms such tachypnea, night sweats, lethargy, and diarrhoea, as well as greater hepatomegaly, splenomegaly, and lymphadenopathy than HIV seronegative patients.

4.Abdominal TB

Depending on the site of involvement, as TB can affect any area from the mouth to the anus, the clinical presentation will vary. The terminal ileum or caecum is the most typical location of involvement, and symptoms commonly include abdominal pain, a palpable mass, weight loss, a fever, and decreased appetite. The characteristic symptoms of tubercular peritonitis include a doughy belly, ascites, abdominal pain, and fever. Additional signs of esophageal TB include dysphagia, odynophagia, and retrosternal pain or discomfort. Additionally, the patient has potentially fatal consequences such a broncho-esophageal fistula and hematemesis. Due to the acidic pH, lack of lymphoid cells in the mucosa, and quick stomach emptying, gastric TB is uncommon. Dyspepsia, duodenal blockage, and duodenal ulcers are symptoms of duodenal TB. Additional reports Perforation, fistulae, and obstructive jaundice are complications. Hematochezia is the typical rectal TB presenting symptom, followed by constitutional symptoms and complications. Additionally, it could manifest as a perirectal abscess, anal fissure, or fistulae.

5.CNS TB

Meningitis, tuberculomas, and abscesses are the most prevalent symptoms of CNS TB (85%, 2%, and 1% respectively). Clinical signs include neck stiffness, headache, vomiting, decreased state of awareness, and those associated with cranial nerve involvement. They may also occur without medical attention. Death and coma

6.Skeletal TB

The most frequent presenting feature is pain. With or without edoema, the affected joints have restricted range of motion. The patient may have sinus tract symptoms. Chronic back pain, fever, and more than 50% of patients experience neurological symptoms as a result of spinal cord compression when the spine is involved. Due to severe, permanent neurological consequences, such as paraplegia, and spinal deformities, a delayed diagnosis could exacerbate the problem.

7.Genito-urinary TB

Local symptoms like dysuria, hematuria, flank pain, and an increased frequency of micturition are how patients typically present. In men, the most typical presentation is scrotal swelling/mass with or without discomfort. In women, genital involvement manifests as pelvic pain, menstrual abnormalities, and infertility. Depending on the location of involvement, symptoms of prostatitis, orchitis, or epididymitis may also appear.

Conclusion

The most effective methods for lowering the risk of TB disease progression in high-risk groups (close contacts, people living with HIV, healthcare workers, etc.) continue to be TB screening (to identify latent TB infection) and prophylactic therapy. These methods should also be taken into consideration in endemic countries to lower the transition from infection to disease. Tools that are extremely sensitive and focused are also necessary for screening for latent TB.

The variety of diagnostic tests currently in use (including the recently launched IGRAs) to diagnose latent tuberculosis are highly specific but less sensitive [146]. Due of their inability to distinguish between illness and latent infection and their high operational costs, In the impoverished world, where the majority of TB infections and illnesses take place, this technology is less than ideal.

The most significant and potent risk factor for TB infection and illness is HIV coinfection. It has been demonstrated that a variety of interventions, including early HIV counselling and screening for TB patients and early diagnosis and beginning of antiretroviral therapy (ART) for coinfected people, are successful in avoiding TB disease [106].

By minimising transmission from infectious individuals, the detection and treatment (via DOTS) of smear-positive cases remains the key to TB control in endemic countries. In endemic countries, untargeted case-finding procedures can help enhance early diagnosis of smear-positive cases in addition to passive case-finding techniques [147]. This is hampered by problems with the health system, such as the high proportion of TB patients who use private healthcare (45% in nations like India) [148]. These people are unknown, and when combined with a delay in diagnosis, they may serve as an ongoing source of TB infection. Therefore, in order to stop the pandemic, efforts must be made to involve private stakeholders (private practitioners, retail pharmacies, and laboratories) in TB control initiatives.

The diagnosis and treatment (through DOTS) of smear-positive cases still holds the key to TB control in endemic nations by reducing transmission from infectious persons. Along with passive case-finding methods, untargeted case-finding strategies in endemic areas can improve early diagnosis of smear-positive cases [147]. Health system issues, such as the significant percentage of TB patients who use private treatment (45% in countries like India), make this difficult [148]. These individuals are unknown, and if a delay in diagnosis is present, they could continue to be a source of TB infection. Therefore, efforts must be taken to include private players (private practitioners, retail pharmacies, and laboratories) in TB control programmes in order to stop the epidemic. against this age-old enemy in all of its guises. This review article represents an honest attempt to raise awareness of TB. I'll sum up by reiterating Sigmund Freud's words.

REFERENCES

1. Ryan KJ, Ray CG. Sherris Medical Microbiology. 5th ed. USA: McGraw Hill company, Inc; 2010:489e505.

2. Sharma SK, Mohan A. Tuberculosis: from an incurable scourge to a curable disease- journey over a Millennium. Indian J Med Res. 2013;137:455e493.

3. Pommerville JC. Alcamo's Fundamentals of Microbiology. 7th ed. Canada: Jones and Bartlett; 2004:284e289

4. Lee JY. Diagnosis and treatment of extrapulmonary tuberculosis. Tuberc Respir Dis. 2015;78:47e55.

5. World Health Organization. Definitions and Reporting Frame Work for Tuberculosis: 2013 Revision. Geneva: World Health Organization; 2013 (updated December 2014)

6. World Health Organization. Global Tuberculosis Report; 2018. Available from: http://www.who.int/tb/publications/global_report/en/.

7. Purohit M, Mustafa T. Laboratory diagnosis of extrapulmonary tuberculosis (EPTB) in resource-constrained setting: state of the art, challenges and the need. J Clin Diagn Res. 2015;9:EE01eEE06.

8. Lange C, Mori T. Advances in the diagnosis of tuberculosis. Journal of Asian Pacific Society of Respiriology. 2010;15:220e240.

9. Sharma SK, Mohan A. Extrapulmonary Tuberculosis. Indian J Med Res. 2004;120:316e353.

10. World Health Organization. Commercial Serodiagnostic Tests for Diagnosis of Tuberculosis, 2011. Geneva: WHO Press; 2011.

11. Sekar B, Selvaraj L, Alexis A, Ravi S, Arunagiri K, Rathinavel L. The utility of IS sequence based polymerase chain reaction in comparison to conventional methods in the diagnosis of extra-pulmonary tuberculosis. Indian J Med Microbiol. 2008;26:352e355.

12. Pingle P, Apte P, Trivedi R. Evaluation of microscopy, culture and PCR methods in the laboratory diagnosis of genitourinary tuberculosis. Am J Infect Dis Microbiol. 2014;2:17e21.

13. Sudhindra KS, Prakash RC, Fathima F, Venkatesh VN, Rao A, Vijaynath V. Evaluation of PCR in early diagnosis of tuberculosis. J Med Res Pract. 2012;1:24e28.

14. Arvind N, Chand P, Baliga S, Bharati B, Shenoi S, Saralaya V. A comprehensive comparison of PCR based assay versus microscopy and culture in the diagnosis of tuberculosis in different clinical specimens. Int J Biol Med Res. 2014;5:3763e3768.

15. Cambau E, Drancourt M. Steps towards the discovery of Mycobacterium tuberculosis by Robert Koch, 1882. Clin Microbiol Infect. 2014;20:196e201.

16. Wallgren A. The time-table of tuberculosis. Tubercle. 1948;29:245e251.

17. Tille PM. Bailey & Scott's Diagnostic Microbiology. 13th ed. Mosby Inc; 2014:484e512.

18. Pfyffer GE, Palicova F. Mycobacterium: general characteristics, laboratory detection, and procedures. In: Versalovic J, Carroll KC, Funke G, Jorgensec JH, Landry ML, Warnock DW, eds. Mannual of Clinical Microbiology. 10th ed. ASN press; 2011:472e502.

19. Bhardwaj AK, Kumar D, Raina SK, Sharma S, Chander V. Assessment of extra pulmonary tuberculosis (EPTB) cases from selected tuberculosis units (TUs) of Himachal Pradesh, India. Int J Health. 2015;3:29e33.

20. World Health Organization. (2015). Global tuberculosis report. 20th ed. World Health Organization; 2015. https://apps.who. int/iris/handle/10665/191102.

21. CDC. Tuberculosis (TB) Testing & Diagnosis.

22. Goering R, Dockrell H, Zuckerman M, Roitt I, Chiodini PL (2012) Mims' medical microbiology. Elsevier Health Sciences.

23. CDC. Tuberculosis (TB) Disease: Symptoms & Risk Factors.

24. Leung AN (1999) Pulmonary tuberculosis: the essentials. Radiol 210(2): 307-322.

25. CDC Multidrug-Resistant Tuberculosis (MDR TB).

26. Fischer B, Ferlinz R (1995) Therapy and prognosis of tuberculosis. Versicherungsmedizin 47(6): 212-216.

27. Brode SK, Varadi R, McNamee J, Malek N, Stewart S, et al. (2015) Multidrug-resistant tuberculosis: Treatment and outcomes of 93 patients. Can Respir J 22(2): 97-102.

28. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, et al. (2014) A four-month gatifloxacin-containing

29. M. A. Behr, S. A. Warren, H. Salamon et al., “Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli,” The Lancet, vol. 353, no. 9151, pp. 444–449, 1999.

30. R. K. Elwood, V. J. Cook, and E. Hernandez-Gardu ´ no, "Risk ˜ of tuberculosis in children from smear-negative source cases," International Journal of Tuberculosis and Lung Disease, vol. 9, no. 1, pp. 49–55, 2005.

31. A. Tostmann, S. V. Kik, N. A. Kalisvaart et al., "Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands," Clinical Infectious Diseases, vol. 47, no. 9, pp. 1135–1142, 2008

32. S. Grzybowski, G. D. Barnett, and K. Styblo, "Contacts of cases of active pulmonary tuberculosis," Bulletin of the International Union against Tuberculosis, vol. 50, no. 1, pp. 90–106, 1975.

33.R. Joshi, A. L. Reingold, D. Menzies, and M. Pai, "Tuberculosis among health-care workers in low- and middle-income countries: a systematic review," PLoS Medicine, vol. 3, no. 12, article e494, 2006.

34.W. H. Frost, "Risk of persons in familial contact with pulmonary tuberculosis," American Journal of Public Health, vol. 23, no. 5, pp. 426–432, 1933.

35.E. L. Opie and F. M. McPhendran, "Spread of tuberculosis within families," The Journal of the American Medical Association, vol. 87, no. 19, pp. 1549–1551, 1926.

36. S. Devadatta, J. J. Dawson, W. Fox et al., "Attack rate of tuberculosis in a 5-year period among close family contacts of tuberculous patients under domiciliary treatment with isoniazid plus PAS or isoniazid alone," Bulletin of the World Health Organization, vol. 42, no. 3, pp. 337–351, 1970.

37. R. H. Andrews, W. Fox, S. Devadatta, and S. Radhakrishna, "Prevalence of tuberculosis among close family contacts of tuberculous patients in South India, and influence of segregation of the patient on the early attack rate," Bulletin of the World Health Organization, vol. 23, pp. 463–510, 1960.

38.S. R. Kamat, J. J. Dawson, S. Devadatta et al., "A controlled study of the influence of segregation of tuberculous patients for one year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India," Bulletin of the World Health Organization, vol. 34, no. 4, pp. 517–532, 1966.

39. J. Morrison, M. Pai, and P. C. Hopewell, "Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis," The Lancet Infectious Diseases, vol. 8, no. 6, pp. 359–368, 2008.

40. D. Menzies, K. Schwartzman, and M. Pai, "Immune-based tests for tuberculosis," in Tuberculosis: A Comprehensive Clinical Reference, H. S. Schaaf and A. Zumla, Eds., pp. 179–196, Elsevier Health Sciences, 2009.